Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain

Gabrielle Campbell, Emily Stockings, Suzanne Nielsen

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)

Abstract

The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30% or 50% reductions in pain severity.

Original languageEnglish
Pages (from-to)135-144
Number of pages10
JournalEuropean Archives of Psychiatry and Clinical Neuroscience
Volume269
Issue number1
DOIs
Publication statusPublished - Feb 2019

Keywords

  • Cannabis
  • Cannabis-based medicines
  • Chronic pain
  • Medical cannabis

Cite this

@article{308dfd34b947411199dc2228c09d872a,
title = "Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain",
abstract = "The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30{\%} or 50{\%} reductions in pain severity.",
keywords = "Cannabis, Cannabis-based medicines, Chronic pain, Medical cannabis",
author = "Gabrielle Campbell and Emily Stockings and Suzanne Nielsen",
year = "2019",
month = "2",
doi = "10.1007/s00406-018-0960-9",
language = "English",
volume = "269",
pages = "135--144",
journal = "European Archives of Psychiatry and Clinical Neuroscience",
issn = "0940-1334",
publisher = "Springer-Verlag London Ltd.",
number = "1",

}

Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain. / Campbell, Gabrielle; Stockings, Emily; Nielsen, Suzanne.

In: European Archives of Psychiatry and Clinical Neuroscience, Vol. 269, No. 1, 02.2019, p. 135-144.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain

AU - Campbell, Gabrielle

AU - Stockings, Emily

AU - Nielsen, Suzanne

PY - 2019/2

Y1 - 2019/2

N2 - The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30% or 50% reductions in pain severity.

AB - The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30% or 50% reductions in pain severity.

KW - Cannabis

KW - Cannabis-based medicines

KW - Chronic pain

KW - Medical cannabis

UR - http://www.scopus.com/inward/record.url?scp=85059893930&partnerID=8YFLogxK

U2 - 10.1007/s00406-018-0960-9

DO - 10.1007/s00406-018-0960-9

M3 - Review Article

VL - 269

SP - 135

EP - 144

JO - European Archives of Psychiatry and Clinical Neuroscience

JF - European Archives of Psychiatry and Clinical Neuroscience

SN - 0940-1334

IS - 1

ER -